Background: Tirofiban is administered for the treatment of aneurysms in cases of thromboembolic complications, as well as in cases of acute stenting or flow-diverter implantation required within the scope of aneurysm treatment. We aimed to investigate the efficacy and safety of tirofiban in this group of patients.
Methods: We conducted a retrospective analysis of all patients undergoing aneurysm treatment and receiving peri-interventional tirofiban administration at our institution between 2009 and 2019.
Results: A total of 105 patients were included, with 61% women and 39% men (mean age = 53 years, IQR: 44-60 years). Sixty-seven patients underwent emergency aneurysm treatment, and thirty-eight were treated electively. Hemorrhagic events occurred in 22% (15/67) of the patients treated acutely, with 7.46% (5/67) exhibiting symptoms. Patients undergoing elective aneurysm treatment experienced no hemorrhagic events (p = 0.002). Among the 35 patients who required an external ventricular drain (EVD), 22.86% (8/35) developed EVD-related hemorrhages; however, none were symptomatic (p = 0.007). Of the five patients who required a craniotomy, two experienced significant bleeding, and one experienced non-significant craniotomy-related bleeding (p = 0.20).
Conclusion: Tirofiban may be safe for use during peri-interventional complications or emergency stenting in aneurysm treatment. However, caution is necessary when craniotomy is required. In elective aneurysm treatments, administering Tirofiban in response to periprocedural complications appears to be safe.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00062-024-01480-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A randomized trial comparing endovascular and surgical management of ruptured intracranial aneurysms excluded from previous trials.
J Neurosurg
January 2025
2Department of Radiology, Service of Interventional Neuroradiology, Centre hospitalier de l'Université de Montréal (CHUM), Montréal.
Objective: Many patients with ruptured intracranial aneurysms (RIAs) underrepresented or excluded from previous randomized controlled trials (RCTs) comparing surgery with endovascular treatment (EVT) are still considered for surgical clipping, but the best management of these patients remains unknown.
Methods: The International Subarachnoid Aneurysm Trial-2 was a randomized trial comparing surgical versus EVT of RIAs considered for surgical clipping, despite the results of previous RCTs, and also eligible for EVT. The primary endpoint was death or dependency according to the modified Rankin Scale score (mRS score > 2) at 1 year.
Hydrogel coils in intracranial aneurysm treatment: a multicenter, prospective, randomized open-label trial.
J Neurosurg
January 2025
19Division of Medical Statistics, Division of Data Science, Foundation for Biomedical Research and Innovation at Kobe; and.
Objective: Studies have demonstrated the effectiveness of hydrogel-coated coils (HGCs) to achieve the composite endpoint of decreased recanalization rates and greater safety. Herein, the authors aimed to assess the true ability of second-generation HGCs to prevent recanalization.
Methods: This randomized controlled study, the HYBRID (Hydrocoil Versus Bare Platinum Coil in Recanalization Imaging Data) trial, comparing HGCs with bare platinum coils (BPCs), was conducted in 43 Japanese institutions.
Transcatheter Aortic Valve Replacement in Patients With Interventricular Membranous Septal Aneurysms.
JACC Case Rep
January 2025
Interventional Cardiology Section, Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.
Aneurysms of the interventricular membranous septum are a rare anatomical feature that can be detected incidentally on computed tomography or echocardiography. Such aneurysms can pose challenges in the treatment of patients with aortic valve stenosis. A case series of 2 patients with membranous septal aneurysms treated successfully with current-generation balloon-expandable and self-expanding transcatheter heart valves is presented here.
View Article and Find Full Text PDFA 65-year-old patient was admitted to the Institute with complaints of shortness of breath, palpitation, and limb edema. Comorbidities were type 2 diabetes mellitus, gout, obesity. Echo: left ventricular ejection fraction 22%, left ventricular aneurysm (LVA), floating thrombus 5.
View Article and Find Full Text PDFThrombolysis for aneurysmal subarachnoid haemorrhage.
Cochrane Database Syst Rev
January 2025
Ageing Clinical and Experimental Research, University of Aberdeen, Aberdeen, UK.
Background: Aneurysmal subarachnoid haemorrhage continues to cause a significant burden of morbidity and mortality despite advances in care. Trials investigating local administration of thrombolytics have reported promising results.
Objectives: - To assess the effect of thrombolysis on improving functional outcome and case fatality following aneurysmal subarachnoid haemorrhage - To determine the effect of thrombolysis on the risk of cerebral artery vasospasm, delayed cerebral ischaemia, and hydrocephalus following subarachnoid haemorrhage - To determine the risk of complications of local thrombolysis in aneurysmal subarachnoid haemorrhage SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (last searched 9 March 2023), MEDLINE Ovid (1946 to 9 March 2023), and Embase Ovid (1974 to 9 March 2023).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!